https://www.youtube.com/watch?v=FrPNIFjLgRw “Dr Toby Maher of the Royal Brompton Hospital, UK, talks about the impact of idiopathic pulmonary fibrosis (IPF) and the need to shed light on this ‘invisible disease’ .” Learn more about IPF:Â http://bit.ly/1QiRmr3…
A potentially important new study, published in the Journal of Biological Chemistry, identified fibroblast activation protein (FAP) as a crucial factor in collagen fragment clearance in the lungs. Clearing collagen fragments is a key step in reducing tissue scarring and restoring lung function following injury, making FAP an interesting target…
New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time. The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity…
“Donald used his own adult stem cells to treat his COPD. He was dealing with cardiologists and pulmonologists, but he just couldn’t see himself getting any better until he tried the stem cell treatment.” Learn more about Stem Cells: http://bit.ly/1Tw7AMJ…
The University of Cincinnati (UC) Medical Center is among the 19 medical centers recently invited after careful review to become part of the Pulmonary Fibrosis Foundation (PFF) Care Center Network. The network now comprises 40 centers across 26 U.S. states with established expertise in the treatment of pulmonary fibrosis…
PRM-151 is a recombinant human serum amyloid P/pentraxin 2 protein developed by Promedior, a biotechnology company developing therapies for fibrotic diseases using plasma-derived proteins and peptides. Also referred to as PTX2, the therapy is injected intravenously in patients and is showing promise as an effective anti-fibrotic agent which can be used to target several…
In a new study, researchers described the insights and perspectives of patients and caregivers regarding the clinical progression of idiopathic pulmonary fibrosis (IPF), and the needs of both at different disease stages. Their article, titled “The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative…
IPF is a progressive, fatal lung disease in which the alveoli and the lung tissue are damaged, becoming thick and scarred (fibrosis), leading to severe breathing difficulties and compromising oxygen transfer between the lungs and the bloodstream. IPF is characterized by a shortness of breath that gradually worsens,…
In this video from schoolofmedicine, meet Hamish S. Osborne and Christine C. Osborne. Mr. Osborne was diagnosed with IPF and had go to through surgery for a double-lung transplant. After that procedure, the couple became parte of the founding supporters of the Program in Lung Healing.
Boehringer Ingelheim Pharmaceuticals, Inc., recently announced the initiation of a trial to compare the safety, tolerability, and pharmacokinetics of adding pirfenidone (Esbriet) to treatment with OFEV (nintedanib, Boehringer Ingelheim) in patients with idiopathic pulmonary fibrosis (IPF). IPF, a type of interstitial lung disease affecting the tissue that supports the…
Get regular updates to your inbox.
